Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription

Chemistry and Biology

Volumn 7, Issue 10, 2000, Pages 793-803

  Coghlan, Matthew P ^a   Culbert, Ainsley A ^a   Cross, Darren AE ^a   Corcoran, Stacey L ^a   Yates, John W ^a   Pearce, Nigel J ^a   Rausch, Oliver L ^a   Murphy, Gregory J ^a   Carter, Paul S ^a   Roxbee Cox, Lynne ^a   Mills, David ^a   Brown, Murray J ^a   Haigh, David ^a   Ward, Robert W ^a   Smith, David G ^a   Murray, Kenneth J ^a   Reith, Alastair D ^a   Holder, Julie C ^a  

^a GLAXOSMITHKLINE   (United Kingdom)

Author keywords

Diabetes; Gene transcription; Glycogen synthase kinase 3; Glycogen synthesis; Protein kinase inhibitor

Indexed keywords

2 (2,4 DICHLOROPHENYL) 3 (1 METHYL 3 INDOLYL)MALEIMIDE; 2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; ADENOSINE TRIPHOSPHATE; AMINOPHENOL DERIVATIVE; BETA CATENIN; CTNNB1 PROTEIN, HUMAN; CYTOSKELETON PROTEIN; GLYCOGEN; GLYCOGEN SYNTHASE; GLYCOGEN SYNTHASE KINASE; GLYCOGEN SYNTHASE KINASE 3; INDOLE DERIVATIVE; MALEIMIDE DERIVATIVE; PROTEIN KINASE; PROTEIN KINASE (CALCIUM,CALMODULIN); RECOMBINANT PROTEIN; TRANSACTIVATOR PROTEIN;

ARTICLE; BINDING COMPETITION; BIOSYNTHESIS; CELL LINE; CHEMICAL STRUCTURE; CYTOLOGY; DEGENERATIVE DISEASE; DRUG ANTAGONISM; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; GENE EXPRESSION REGULATION; GENETIC TRANSCRIPTION; GENETICS; HUMAN; KINETICS; LIVER; METABOLISM; NON INSULIN DEPENDENT DIABETES MELLITUS; REPORTER GENE; SIGNAL TRANSDUCTION;

ADENOSINE TRIPHOSPHATE; AMINOPHENOLS; BETA CATENIN; BINDING, COMPETITIVE; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CELL LINE; CYTOSKELETAL PROTEINS; DIABETES MELLITUS, TYPE 2; ENZYME ACTIVATION; GENE EXPRESSION REGULATION; GENES, REPORTER; GLYCOGEN; GLYCOGEN SYNTHASE; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASES; HUMANS; INDOLES; KINETICS; LIVER; MALEIMIDES; MOLECULAR STRUCTURE; NEURODEGENERATIVE DISEASES; PROTEIN KINASES; RECOMBINANT PROTEINS; SIGNAL TRANSDUCTION; TRANS-ACTIVATORS; TRANSCRIPTION, GENETIC;

EID: 0033776383     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1074-5521(00)00025-9     Document Type: Article

References (48)

1. Molecular cloning and expression of glycogen synthase kinase-3/factor A
2. Muscle glycogen synthase
3. Phosphorylation of insulin receptor substrate-1 by glycogen synthase kinase-3 impairs insulin action
4. Regulation of eukaryotic initiation factor elF2B: Glycogen synthase kinase-3 phosphorylates a conserved serine which undergoes dephosphorylation in response to insulin
5. Glycogen synthase kinase-3 phosphorylates Jun family members in vitro and negatively regulates their transactivating potential in intact cells
6. A secondary phosphorylation of CREB341 at Ser129 is required for the cAMP-mediated control of gene expression. A role for glycogen synthase kinase-3 in the control of gene expression
7. Nuclear export of NF-ATc enhanced by glycogen synthase kinase-3
8. Down regulation of β-catenin by human Axin and its association with the APC tumor suppressor, β-catenin and GSK3-β
9. Glycogen synthase kinase-3 is an insulin-regulated C/EBPα kinase
10. Inhibition of GSK-3β leading to the loss of phosphorylated MAP-1B is an early event in axonal remodelling induced by wnt-7a or lithium
11. Glycogen synthase kinase-3β phosphorylation of MAP-1B regulates the stability of microtubules in growth cones
12. Lithium reduces tau phosphorylation by inhibition of glycogen synthase kinase-3
13. Glycogen synthase kinase-3β phosphorylates tau protein at multiple sites in intact cells
14. Tau is phosphorylated by GSK-3 at several sites found in Alzheimer disease and its biological activity markedly inhibited only after it is prephosphorylated by A-kinase
15. Lithium inhibits Alzheimer's disease-like tau protein phosphorylation in neurons
16. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
17. Inactivation of glycogen synthase kinase-3 by epidermal growth factor is mediated by mitogen-activated protein kinase/p90 ribosomal protein S6 kinase signaling pathway in NIH/3T3 cells
18. The inhibition of glycogen synthase kinase-3 by insulin or insulin-like growth factor 1 in the rat skeletal muscle cell line L6 is blocked by wortmannin, but not by rapamycin: Evidence that wortmannin blocks activation of the mitogen-activated protein kinase pathway in L6 cells between Ras and Raf
19. The mechanism by which epidermal growth factor inhibits glycogen synthase kinase-3 in A431 cells
20. Wortmannin inhibits the effects of insulin and serum on the activities of glycogen synthase kinase-3 and mitogen-activated protein kinase
21. T-cell activation leads to rapid stimulation of translation initiation factor elF2B and inactivation of glycogen synthase kinase-3
22. Regulation of protein kinase B and glycogen synthase kinase-3 by insulin and β-adrenergic agonists in rat epididymal fat cells. Activation of protein kinase B by wortmannin-sensitive and -insensitive mechanisms
23. Nerve and epidermal growth factor induce protein synthesis and elF2B activation in PC12 cells
24. Wnt-1 and HGF regulate GSK3-β activity and β-catenin signaling in mammary epithelial cells
25. Cell-extracellular matrix interactions stimulate the AP-1 transcription factor in an integrin-linked kinase- and glycogen synthase kinase 3-dependent manner
26. Tau-protein kinase-I is essential for amyloid beta-protein-induced neurotoxicity
27. Role of glycogen synthase kinase-3β in neuronal apoptosis induced by trophic withdrawal
28. A good antisense molecule is hard to find
29. A molecular mechanism for the effect of lithium on development
30. Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells
31. The role of glycogen synthase kinase-3β in insulin-stimulated glucose metabolism
32. The specificities of some commonly used protein kinase inhibitors and the mechanism of action of U0126
33. Lithium therapy and signal transduction
34. Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons
35. The development and therapeutic potential of protein kinase inhibitors
36. Protein kinase inhibitors: Structural determinants for target specificity
37. Potential role of glycogen synthase kinase-3 in skeletal muscle insulin resistance of type 2 diabetes
38. Increased glycogen synthase kinase-3 activity in diabetes- and obesity-prone C57BL/6J mice
39. Possible role of tau protein kinases in pathogenesis of Alzheimers disease
40. Insulin stimulated glycogen synthesis in isolated rat hepatocytes: Effect of protein kinase inhibitors
41. Insulin activates protein kinase B, inhibits glycogen synthase kinase-3 and activates glycogen synthase by rapamycin-insensitive pathways in skeletal muscle and adipose tissue
42. Insulin-stimulated glycogen synthesis in cultured hepatoma cells: Differential effects of inhibitors of insulin signalling molecules
43. 2+ pathways
44. New insights into the role and mechanism of glycogen synthase activation by insulin
45. Effects of lithium ions on glycogen synthase and phosphorylase in rat hepatocytes
46. Inhibitors of protein kinase C. 1. 2,3-Bisarylmaleimides
47. Site-specific anti-phosphopeptide antibodies: Use in assessing insulin receptor serine/threonine phosphorylation state and identification of serine-1327 as a novel site of phorbol ester-induced phosphorylation